CN105456563A - 一种改善肠道功能的组合物 - Google Patents
一种改善肠道功能的组合物 Download PDFInfo
- Publication number
- CN105456563A CN105456563A CN201510998814.3A CN201510998814A CN105456563A CN 105456563 A CN105456563 A CN 105456563A CN 201510998814 A CN201510998814 A CN 201510998814A CN 105456563 A CN105456563 A CN 105456563A
- Authority
- CN
- China
- Prior art keywords
- composition
- inulin
- compositions
- banana powder
- lactitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000003871 intestinal function Effects 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 9
- 229920001202 Inulin Polymers 0.000 claims abstract description 7
- 241000219823 Medicago Species 0.000 claims abstract description 7
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims abstract description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 7
- 229940029339 inulin Drugs 0.000 claims abstract description 7
- 235000012054 meals Nutrition 0.000 claims abstract description 6
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 5
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 5
- 230000000968 intestinal effect Effects 0.000 claims description 18
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000006041 probiotic Substances 0.000 abstract description 10
- 235000018291 probiotics Nutrition 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 210000000813 small intestine Anatomy 0.000 abstract description 3
- 206010010774 Constipation Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000234295 Musa Species 0.000 abstract 3
- 235000018290 Musa x paradisiaca Nutrition 0.000 abstract 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 abstract 2
- 229960003451 lactitol Drugs 0.000 abstract 2
- 235000010448 lactitol Nutrition 0.000 abstract 2
- 239000000832 lactitol Substances 0.000 abstract 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 abstract 1
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
- 210000002429 large intestine Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 3
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种改善肠道功能的组合物，所述组合物由乳双歧杆菌、嗜酸乳杆菌、嗜热链球菌、副干酪乳杆菌、菊粉、乳糖醇、香蕉粉和苜蓿粉组成；所述组合物中各组分协同增效，复配的菊粉和乳糖醇等更好的保持益生菌的活力，同时还添加了苜蓿提取物和香蕉粉，其中苜蓿提取物增强了组方清脾胃湿热、利大小肠、下膀胱结石的功效，香蕉粉增强了组方润肠通便的效果，全面调理胃肠道健康；所述组合物稳定性好，可直接作用于小肠具有良好的黏附性，尤其适合于东方人的体质。
Description
技术领域
本发明涉及一种组合物，尤其是一种改善肠道功能的组合物。
背景技术
随着生活节奏的日益加快，快餐行业垃圾食品的泛滥以及不规则的饮食习惯等，使胃肠的健康问题成为当今的社会性问题。针对这样的问题，益生菌食品被越来越多的人所认知，熟悉。现代人在饮食中摄入的益生菌的数量越来越少。许多食品和包装越来越多地使用人工合成的原材料，而且在食品中添加防腐剂、增稠剂、香精、香料等人工合成的添加剂，人们过多食用这些加工食品，极不利于体内益生菌群的生存与增殖。随着城市化、工业化的发展，环境污染越来越重，生态环境不断恶化，人类赖以生存的空气和水质量不断下降。城市饮用水往往必须经过自来水工厂的净化技术处理，尤其是经过氯处理后，含氯的饮用水会损害人体内的益生菌生长繁殖。现代人的工作生活紧张、压力增大，益生菌对人体的压力状况极为敏感。因为压力增大会改变人体内的荷尔蒙平衡，导致人体内的益生菌群数量减少。饮食中大量的精细碳水化合物和糖类会促进有害菌和酵母的生长且抑制有益细菌的繁殖。膳食中过多的肉类和过少的蔬菜水果会削弱益生菌的活性。抗生素的普及和滥用给人体会带来诸多的副作用。抗生素类药物在杀死体内有害菌的同时，也会杀死体内的有益菌。因此，专家们指出，要维护人体健康，现代人要面对这些种种不利因素，更需要经常性额外补充益生菌以改善肠道功能。
发明内容
本发明所要解决的技术问题在于提供一种改善肠道功能的组合物。
为解决上述技术问题，本发明的技术方案是：
一种改善肠道功能的组合物，由乳双歧杆菌(BifidobacteriumlactisHN019)、嗜酸乳杆菌(LactobacillusacidophilusNCFM)、嗜热链球菌(st-21)、副干酪乳杆菌(Lpc-37)、菊粉、乳糖醇、香蕉粉和苜蓿粉组成，按其重量份数计：
根据权利要求1所述的改善肠道功能的组合物，其特征在于：按其重量份数计：
优选的，上述改善肠道功能的组合物，按其重量份数计：
本发明的有益效果是：
上述改善肠道功能的组合物，各组分协同增效，复配的菊粉和乳糖醇等更好的保持益生菌的活力，同时还添加了苜蓿提取物和香蕉粉，其中苜蓿提取物增强了组方清脾胃湿热、利大小肠、下膀胱结石的功效，香蕉粉增强了组方润肠通便的效果，全面调理胃肠道健康；所述组合物稳定性(耐胃酸、耐胆汁)好，可直接作用于小肠具有良好的黏附性，尤其适合于东方人的体质。
附图说明
图1是抗生素使用期间及治疗后本发明所述组合物干预疗效图。
具体实施方式
下面结合具体实施例对本发明所述技术方案作进一步的说明。
其中，所采用的益生菌选用丹尼斯克公司的菌种。
实施例1
一种改善肠道功能的组合物，由乳双歧杆菌(BifidobacteriumlactisHN019)、嗜酸乳杆菌(LactobacillusacidophilusNCFM)、嗜热链球菌(st-21)、副干酪乳杆菌(Lpc-37)、菊粉、乳糖醇、香蕉粉和苜蓿粉组成，具体用量见表1，所述组合物是由下述方法获得的：
(1)按组方量称取乳双歧杆菌(BifidobacteriumlactisHN019)、嗜酸乳杆菌(LactobacillusacidophilusNCFM)、嗜热链球菌(st-21)、副干酪乳杆菌(Lpc-37)、菊粉、乳糖醇、香蕉粉和苜蓿粉为原料；
(2)将各组分混合均匀，即得。
表1
实施例2
实施例1-1所述改善肠道功能的组合物的功效实验
研究对象：40名成年患者，平均年龄37.2岁。
试验设计：随机、双盲、对照试验研究，共持续48天。第1、7、14天时，采集试验者粪便样本，自第14天起，患者口服阿莫西林克拉维酸钾(GSK生产)875mg，每日两次，连服七天。在第21、25、34、48天时继续采集粪便标本。实验组和对照组干预时间为第14天至34天。
试验分组：实验组，20人：空腹口服实施例1-1所述组合物，每日两次，每次2g。
对照组，20人：空腹口服安慰剂(麦芽糊精)，每日两次，每次2g。
评价指标：通过对粪便中微生物的评估检测生物标记物，进而评估抗生素使用期间及治疗后本发明所述组合物干预的疗效，结果见图1。
由图1可以看出，抗生素治疗后两周，实验组患者肠道内总菌群数量仍保持至治疗前水平，本发明所述组合物可帮助机体在抗生素治疗期间，快速重建肠道内微生态环境，改善肠道功能。
上述参照实施例对该一种改善肠道功能的组合物进行的详细描述，是说明性的而不是限定性的，可按照所限定范围列举出若干个实施例，因此在不脱离本发明总体构思下的变化和修改，应属本发明的保护范围之内。
Claims (3)
1.一种改善肠道功能的组合物，其特征在于：由乳双歧杆菌、嗜酸乳杆菌、嗜热链球菌、副干酪乳杆菌、菊粉、乳糖醇、香蕉粉和苜蓿粉组成，按其重量份数计：
2.根据权利要求1所述的改善肠道功能的组合物，其特征在于：按其重量份数计：
3.根据权利要求1所述的改善肠道功能的组合物，其特征在于：按其重量份数计：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510998814.3A CN105456563A (zh) | 2015-12-25 | 2015-12-25 | 一种改善肠道功能的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510998814.3A CN105456563A (zh) | 2015-12-25 | 2015-12-25 | 一种改善肠道功能的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456563A true CN105456563A (zh) | 2016-04-06 |
Family
ID=55595020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510998814.3A Pending CN105456563A (zh) | 2015-12-25 | 2015-12-25 | 一种改善肠道功能的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456563A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105901548A (zh) * | 2016-04-12 | 2016-08-31 | 河南农业大学 | 一种苜蓿火腿肠的制备方法 |
| CN106072657A (zh) * | 2016-06-08 | 2016-11-09 | 天津隆顺榕发展制药有限公司 | 益生菌组合物及其制备方法 |
| CN109198646A (zh) * | 2018-10-29 | 2019-01-15 | 广州普维君健药业有限公司 | 具有防治肠道炎症性疾病功效的益生菌组合物及其应用 |
| CN113197311A (zh) * | 2020-07-03 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 一种乳酸菌组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102438589A (zh) * | 2009-03-09 | 2012-05-02 | 益生菌股份公司 | 用于儿科应用的含益生菌的油性悬浮液 |
| CN102470152A (zh) * | 2009-07-30 | 2012-05-23 | 丹尼斯科公司 | 用于治疗内毒素血症的乳酸菌和双歧杆菌 |
| CN105124333A (zh) * | 2015-09-02 | 2015-12-09 | 曹博雅 | 一种含益生菌组合物及其制备方法和应用 |
-
2015
- 2015-12-25 CN CN201510998814.3A patent/CN105456563A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102438589A (zh) * | 2009-03-09 | 2012-05-02 | 益生菌股份公司 | 用于儿科应用的含益生菌的油性悬浮液 |
| CN102470152A (zh) * | 2009-07-30 | 2012-05-23 | 丹尼斯科公司 | 用于治疗内毒素血症的乳酸菌和双歧杆菌 |
| CN105124333A (zh) * | 2015-09-02 | 2015-12-09 | 曹博雅 | 一种含益生菌组合物及其制备方法和应用 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105901548A (zh) * | 2016-04-12 | 2016-08-31 | 河南农业大学 | 一种苜蓿火腿肠的制备方法 |
| CN106072657A (zh) * | 2016-06-08 | 2016-11-09 | 天津隆顺榕发展制药有限公司 | 益生菌组合物及其制备方法 |
| CN109198646A (zh) * | 2018-10-29 | 2019-01-15 | 广州普维君健药业有限公司 | 具有防治肠道炎症性疾病功效的益生菌组合物及其应用 |
| CN113197311A (zh) * | 2020-07-03 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 一种乳酸菌组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7546829B2 (ja) | 泌尿生殖器の酵母感染症および細菌感染症の治療に適したプロバイオティクスなラクトバチルス・クリスパタス株 | |
| Liu et al. | Effects of Lactobacillus brevis preparation on growth performance, fecal microflora and serum profile in weaned pigs | |
| Timmerman et al. | Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy | |
| CN106834187B (zh) | 一种两歧双歧杆菌及其用途 | |
| AU2011209407B2 (en) | Probiotic composition for use in the treatment of bowel inflammation | |
| EP2990045B1 (en) | Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman | |
| CN103637219A (zh) | 益生菌组合物及其应用、婴幼儿食品 | |
| CN107691955A (zh) | 益生菌固体饮料及其制备方法 | |
| MXPA03005465A (es) | Compuestos probioticos derivados de la cepa ke01 de lactobacillus casei. | |
| CN107308190A (zh) | 调节人体微生态平衡的益生菌组合物及其培养物、制剂、用途 | |
| CN104171582A (zh) | 一种低胆固醇鸡蛋的生产方法 | |
| ES2675309T3 (es) | Uso de una cepa de Lactobacillus rhamnosus para reducir la ganancia de peso y/o la resistencia a la insulina | |
| CN105456563A (zh) | 一种改善肠道功能的组合物 | |
| CN113197311B (zh) | 一种乳酸菌组合物及其制备方法 | |
| CN115838675B (zh) | 一种鼠李糖乳杆菌及其组合物与应用 | |
| WO2014096901A1 (en) | Strain of bifidobacterium animalis ssp. animalis | |
| EP1996696A2 (en) | Thermostable lactobacillus strains | |
| CN108576823A (zh) | 一种抗氧化、抗衰老的合生元组合物及其制剂与应用 | |
| CN106727725A (zh) | 一种治疗肠道菌群紊乱的益生菌肠溶胶囊及其囊体 | |
| CN110432494A (zh) | 防治婴幼儿过敏性湿疹和/或腹泻的益生菌组合物和应用 | |
| CN111602761A (zh) | 一种缓解或治疗肠易激综合症的益生菌固体饮料 | |
| El-Ezabi et al. | The viability of probiotics as a factor influencing the immune response in the Nile tilapia, Oreochromis niloticus | |
| CN116746683A (zh) | 防消化不良胀气、促吸收的动物双歧杆菌乳亚种bal-28及发酵产物、菌群cw和应用 | |
| WO2009068474A1 (en) | Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect | |
| Wang et al. | Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160406 |